--- title: "Coeptis Wins Nasdaq Nod for Z Squared Merger Listing" type: "News" locale: "en" url: "https://longbridge.com/en/news/282022098.md" description: "Coeptis Therapeutics Holdings has received Nasdaq approval for the listing of its common stock under the ticker \"ZSQR\" following its merger with Z Squared Inc. This approval is contingent on customary closing conditions and follows shareholder approval at the January 30, 2026 meeting. The merger is expected to close in Q2 2026, with Z Squared becoming a wholly owned subsidiary, focusing on Dogecoin and Litecoin mining. Coeptis is a biopharmaceutical company developing innovative therapies and AI-powered tools." datetime: "2026-04-08T10:32:58.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/282022098.md) - [en](https://longbridge.com/en/news/282022098.md) - [zh-HK](https://longbridge.com/zh-HK/news/282022098.md) generator: "portal-rs" --- # Coeptis Wins Nasdaq Nod for Z Squared Merger Listing ### Easter Sale - 70% Off TipRanks - Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions - Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks Coeptis Therapeutics Holdings ( (COEP) ) just unveiled an announcement. On April 7, 2026, Coeptis Therapeutics Holdings announced that Nasdaq had approved, subject to customary closing conditions, the listing of the post-merger company’s common stock on the Nasdaq Global Market under the ticker “ZSQR” following its planned merger with digital infrastructure miner Z Squared Inc. The approval, which comes after effectiveness of Coeptis’ Form S-4 registration statement and shareholder approval at the January 30, 2026 stockholders’ meeting, satisfies a key closing condition for a transaction expected to close in the second quarter of 2026, after which Z Squared will be a wholly owned subsidiary and the combined entity will operate under the Z Squared Inc. name with a focus on institutional-scale Dogecoin and Litecoin mining. **More about Coeptis Therapeutics Holdings** Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical and technology company whose subsidiaries focus on developing innovative cell therapy platforms targeting cancer, autoimmune and infectious diseases, while also building AI-powered marketing and robotic process automation tools to enhance operations. Its therapeutic portfolio includes an allogeneic cellular immunotherapy platform and DVX201 natural killer cell therapy licensed from Deverra Therapeutics, a universal multi-antigen CAR technology from the University of Pittsburgh, and GEAR cell therapy and companion diagnostics developed with VyGen-Bio and researchers at the Karolinska Institute. **Average Trading Volume:** 50,751 **Technical Sentiment Signal:** Sell **Current Market Cap:** $65.09M For a thorough assessment of COEP stock, go to TipRanks’ Stock Analysis page. ### Related Stocks - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [IHE.US](https://longbridge.com/en/quote/IHE.US.md) - [COEPW.US](https://longbridge.com/en/quote/COEPW.US.md) - [VHT.US](https://longbridge.com/en/quote/VHT.US.md) - [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md) - [COEP.US](https://longbridge.com/en/quote/COEP.US.md) - [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [ZSQR.US](https://longbridge.com/en/quote/ZSQR.US.md) ## Related News & Research - [Moderna surges on trial win for cancer shot; William Blair upgrades](https://longbridge.com/en/news/296370751.md) - [U.S. kindergarten vaccine coverage falls, CDC says](https://longbridge.com/en/news/296136711.md) - [SBIO: U.S. Programmatic and EMEA drove 49% of Q2 sales, with margins rising to 61% and profitability expected in H2 2026](https://longbridge.com/en/news/296517769.md) - [Guotai Asset Management sees liquidity boost driving China biotech, innovation drug shares higher](https://longbridge.com/en/news/296448906.md) - [How Stronger Earnings Guidance and SHOP Expansion Will Impact LTC Properties (LTC) Investors](https://longbridge.com/en/news/296279738.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**